MARVELD1 and neoplasm: We found 63.6% (21 out of 33 NSCLC) in grade I tumor showed the reduced MARVELD1 expression, but 96.9% (62 out of 64) in the advanced grades (grade II to III) (Table S2, P < 0.001).